The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 22, 2014
Filed:
Apr. 01, 2011
Nam-soon Kim, Daejeon, KR;
In-sung Song, Daejeon, KR;
Cheol-hee Kim, Daejeon, KR;
GA Hee Ha, Daejeon, KR;
Hyun-taek Kim, Daejeon, KR;
So-young Jeong, Daejeon, KR;
Jeong-min Kim, Daejeon, KR;
Joo Heon Kim, Daejeon, KR;
Jin-man Kim, Daejeon, KR;
Soo Young Jun, Daegu, KR;
Nam-Soon Kim, Daejeon, KR;
In-Sung Song, Daejeon, KR;
Cheol-Hee Kim, Daejeon, KR;
Ga Hee Ha, Daejeon, KR;
Hyun-Taek Kim, Daejeon, KR;
So-Young Jeong, Daejeon, KR;
Jeong-Min Kim, Daejeon, KR;
Joo Heon Kim, Daejeon, KR;
Jin-Man Kim, Daejeon, KR;
Soo Young Jun, Daegu, KR;
Korea Research Institute of Bioscience and Biotech, Daejeon, KR;
Abstract
The present invention relates to a pharmaceutical composition, including inhibitors for expression or activity of TIP41 protein, for prevention and treatment of cancer. When the liver cancer cell lines, showing resistance to TRAIL, are treated with TIP41 siRNA and TRAIL, apoptosis is induced in cancer cell. The same effect is found in cases of lung cancer and colon cancer with resistance against TRAIL. Moreover, this induction of apoptosis by TIP41 siRNA and TRAIL was confirmed in tumor xenograft, which was injected with Huh7 liver cancer cells and then was subjected to TIP41 siRNA transfection and TRAIL treatment. In addition, it was confirmed through animal experiments in which the tumor size has reduced and apoptosis was induced by treatment with TIP41 siRNA and TRAIL. Of note, MKK7/JNK pathway was confirmed to mediate the apoptosis induced by the application of TIP41 siRNA and TRAIL. The apoptosis were verified to be caused by the activation of MKK7/JNK signaling pathway. Taken together, the present invention provide the strong evidence that the pharmaceutical composition, including inhibitors for TIP41 expression or activity can be used for cancer prevention and treatment as well as an anti-cancer adjuvant. Taken together, the pharmaceutical composition comprising inhibitors for expression or activity of TIP41 protein may be used for prevention and treatment of cancer or as an anti-cancer adjuvant.